1 / 96

Health Care associated infection/pathology of the Central Nervous System

Health Care associated infection/pathology of the Central Nervous System. Professor Mary Cafferkey Associate Professor of Clinical Microbiology, RCSI. Which infections?. Acute infection Encephalitis Meningitis Meningoencephalitis Abscess Chronic infection

brody-gates
Download Presentation

Health Care associated infection/pathology of the Central Nervous System

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Health Care associated infection/pathology of the Central Nervous System Professor Mary Cafferkey Associate Professor of Clinical Microbiology, RCSI

  2. Which infections? Acute infection • Encephalitis • Meningitis • Meningoencephalitis • Abscess Chronic infection Post-infectious and post-immunisation complications Transmissable spongioform encephalopathies

  3. Scope • Procedure-Related • Other Intervention related • Medicinal substance • Transfusion of Blood or Blood products • Transplantation • Immunisation • Exposure to infection in a Health Care setting

  4. Procedure-related • Lumbar puncture/Epidural anaesthesia • CNS electrodes • Procedures involving the Central Nervous System • Craniotomy • CSF Shunt placement/removal/revision • Operative procedures • Exploration/lobectomy/abscess drainage/excision of tumour etc

  5. Lumbar puncture/epidural anaesthesia etc. • Risk • Organism • Prevention • Diagnosis and management

  6. Lumbar Puncture With aseptic technique, negligible risk of meningitis following lumbar puncture Theoretical risk in patient with bacteraemia at the time of the procedure Image: Anaesthesiauk

  7. Epidural Anaesthesia Short-term – for several days Subcutaneously tunnelled may be left in place for longer (months) Very low risk of infection with careful aseptic technique; ? Risk with Bacteraemia Case reports and small series in the literature Images: Wikipedia.org

  8. Spinal anaesthesia Very low risk of infection with careful aseptic technique ? Risk with bacteremia Case reports & small series in the literature

  9. CNS electrodes • Spinal cord, brain • Very low risk with careful aseptic technique • The literature in the last 10+ years has concentrated on the risk of transmissable spongioform encephalopathies (TSEs)

  10. Surgical Procedures involving the CNS • Craniotomy • CSF Shunt placement/removal/revision • Operative procedures • Exploration/lobectomy/abscess drainage/excision of tumour etc

  11. CSF Shunt placed: • Treatment of hydrocephalus • To relieve pressure in PTC/IIH Shunt or access device: • To administer cytotoxic agents or, rarely, painkillers (morphine)

  12. Ventriculoperitoneal (VP) and ventroculoatrial (VA) shunts

  13. Ommaya Reservoir

  14. Instillation of agent into Ommaya Reservoir

  15. Indications for shunt placement:Paediatrics • Hydrocephalus • Congenital • Aqueductal stenosis, Chiari malformations, Cysts, vascular malformations • Acquired • Postmeningitic or post-inflammatory, IVH, Tumour • Hydraencephaly

  16. Indications for shunt placement:Adults Conen et al., Clin Infect Dis 2008:47:73-82

  17. Pople I. J Neurol Neurosurg Psychiatry 2002;73:i17-22

  18. CNS Shunt complications • Infection • Obstruction • Proximal end, protein accumulation • [Distal end, protein accumulation] • Valve obstruction or malfunction • Catheter disconnection, kinking or migration • Overdrainage • Extra-axial fluid collection and brain compression • Subdural haematoma • Chiara 1 malformation • Slit Ventricle • Intraventricual haemorrhage

  19. CNS Shunt Complications Substantial morbidity and risk of mortality Long term complications • Cognitive defects • Neurological problems • Death

  20. Criteria for nosocomial Shunt Infection (modified CDC) • Growth of a pathogen in the CSF, from the shunt tip, or in wounds overlying the implanted material OR • Fever (>38oC), headache, neck stiffness, cranial nerve signs or irritability without another recognised cause, physician initiation of antimicrobial therapy, and CSF leukocyte count >5 x106/L, CSF protein >0.45g/L, CSF:Blood glucose ratio <0.5, organisms seen on CSF Gram stain, or organisms isolated from blood culture

  21. CNS Shunt Infection Occurs in up to c.20% • Most common in the first 6 months after surgery • Most common in those shunted at <6 months • Risk may vary with cause of hydrocephalus • Incidence decreases with increasing age • The risk of infection is greater with a VA than with a VP shunt Independent risk factors • Previous shunt infection • Shunt dysfunction • Post-operative leakage of CSF • Experience of the neurosurgeon • Duration of the operative procedure

  22. Ferguson SD et al, Observations Regarding Failure of Cerebrospinal Fluid Shunts Early After Implantation NeurosurgFocus 2007;22:E7University of Chicago Children’s Hospital • Retrospective review of 396 shunt placement procedures during an 8-year period • Data collected on patient age, race, indication for shunting, origin of hydrocephalus, shunt type, date of shunt revision or removal, and number of subsequent revisions • For failure due to shunt malfunction – data was obtained on the cause of failure (obstruction of valve, proximal catheter or distal catheter) • For cases of infection, the identity of the causative organism was recorded

  23. Ferguson SD et al, Observations Regarding Failure of Cerebrospinal Fluid Shunts Early After Implantation NeurosurgFocus 2007;22:E7University of Chicago Children’s Hospital • 396 shunt procedures • 116 shunts failed (90 patients) • M:59%, non-white 54.3% • Shunts were placed for hydrocephalus 87.9%, PTC 12.1% • Mean survival time of newly placed shunts - 6.3 +/- 11.8 months • Shunt failures • Malfunction 83 (71.5%) • Infection 33 (28.5%) • Pathogens • Staph epi 54% • MSSA 25% • MRSA 12% • Ps aeruginosa 3% • Others inc Serratia & Corynebacterium 6%

  24. Ferguson SD et al, Observations Regarding Failure of Cerebrospinal Fluid Shunts Early After Implantation NeurosurgFocus 2007;22:E7University of Chicago Children’s Hospital • 116 shunts failed • Mean survival time of newly placed shunts - 6.3 +/- 11.8 months • Malfunction 7.1+/- 12.2 • Infection 4.3 +/- 10.7 • Shunt failures • Malfunction 83 (71.5%) • Infection 33 (28.5%) • The origins of hydrocephalus were similar in the 2 groups • Shunts for Hydrocephalus longer survival than for PTC (p = 0.051) • Shunts placed age 0-6 mo shorter survival than those after age 6 mo (p = 0.067) • Shunts with malfunction almost x2 as likely to last longer than 6 months than with infection (p<0.05) • Mean shunt survival period almost 7 times greater in white than non-white, 20.4 vs 3.1 mo, ANOVA p <0.05

  25. Clin Infect Dis 2008:47:73-82

  26. Findings • 48 (62%) of infections within 1 month of surgery • 61 (78%) had fever • 35 (45%) had neck stiffness • 38 (49%) had local signs of inflammation • 80% had CSF leukocyte count >5 x106/L • 81% had elevated CSF lactate • 52% had CSF:blood glucose ratio <0.5 • 58% had CSF protein >0.45g/L Conen et al., Clin Infect Dis 2008:47:73-82

  27. Conen et al., Clin Infect Dis 2008:47:73-82

  28. Conen et al., Clin Infect Dis 2008:47:73-82

  29. Sciubba DM et al, Factors contributing to the Medical Costs of Cerebrospinal Fluid Shunt Infection Treatment in Pediatric Patients with Standard Shunt Components Compared with Antibiotic-impregnated Components NeurosurgFocus 2007;22:E9 Johns Hopkins • Retrospective review • Pediatric patients age range 1-16 years who underwent shunt insertion for hydrocephalus over a 3 year period • Patient FU 12 mo after surgery. • N = 211 patients had 353 shunting procedures; • M:F 195:158, 55%:45% • Shunt type • VP 326 (92%), VPL 17 (5%), VA 10 (3%) • The AIS cohort were younger, more frequently premature, had a greater incidence of ICH and more frequently had programmable valves

  30. 211 patients had 353 shunting procedures; 208 standard shunts, 145 AISs (if full system, clindamycin and rifampicin) After adjusting for intercohort differences, on multivariate analysis, AIS catheters were independently associated with a 2.4-fold decreased likelihoood of shunt infection (relative risk = 0,041, 95% CI 0.32-0.52, p<0.01 Sciubba DM et al, Factors contributing to the Medical Costs of Cerebrospinal Fluid Shunt Infection Treatment in Pediatric Patients with Standard Shunt Components Compared with Antibioticimpregnated Components NeurosurgFocus 2007;22:E9

  31. Tuan TJ et al. Treatment and Microbiology of Repeated Cerebrospinal Fluid Shunt Infections in Children Ped Inf Dis J 2011;30 731-735University of California at San Francisco • n = 31 with second shunt infections (SI-2) • Age <6 mo at initial shunt placement 81% • Male 77% • VP shunt 71% • 18 developed SI-3 (60%) and 8, SI-4 (47%) • The median time to SI-3 was 477 days (range 2-828 days) and SI-4 was 2137 days (range 9-2137 days) • Gram positive organisms predominated (SI-2 93%, SI-3 94%) “Children with SI-2 experience high subsequent reinfection rates with a long time to reinfection”

  32. Prevention of CNS shunt infections • Surgical site preparation • Prophylactic antibiotics • “Care bundle” • Antimicrobial impregnanted catheters • Antimicrobial impregnanted sutures

  33. Surgical prophylaxis Neurosurgery • Prophylaxis is not effective in reducing infection rates with intracranial pressure monitors – retrospective analysis n = 215, J Neurol Neurosurg Psych 2000;69:381 Recommended for • Clean non-implant surgery (e.g., craniotomy) • Clean, contaminated surgery (through sinuses or oro/nasopharynx) • Insertion of CSF shunt

  34. Clean, non-implant Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy, Antimicrobial prophylaxis in neurosurgery and after head injury Lancet 1994;344:1547-51 cefazolin 1-2G iv single dose alternative vancomycin 1 g iv single dose

  35. Clean, contaminated • Clean, contaminated (through sinuses or oro/nasopharynx) • clindamycin 900mg iv single dose, or amoxicillin-clavulinic acid 1.2g single dose or cefuroxime 1.5g iv single dose plus metrondidazole 500mg iv single dose

  36. CSF Shunt Insertion • Meta-analysis suggests benefit of prophylaxis (Cochrane Database 3:CD005365, 2006) • Cefazolin 1-2g iv single dose, alternative vancomycin 1g iv single dose • In a hospital with a high prevalence of MRSA infection, vancomycin was more effective (J Hosp Infect 2008;69:337

  37. Quality Improvement/”Care Bundle”

  38. Management of Infection

  39. Causes of HCA meningitis/encephalitis/ encephalopathy

  40. The Patient • Exposure/Cross-infection • Varicella-zoster, influenza virus, measles virus, Mycobacterium tuberculosis, (N. meningitidis) • Transfusion/Transplantation • Cytomegalovirus, Epstein-Barr Virus, West Nile Virus, Tick-borne encephalitis, rabies, T. pallidum,R. rickettsiae, C. neoformans, Coccidioidesspp, H. capsulatum,Toxoplasmagondii, human parvovirus (parvovirus B19), CJD, vCJD Black : N. Europe

  41. Transplant Recipients HCAInfections that may involve the CNS Recipients of: Haemopoietic cell transplantation – HCT Solid Organ transplant – SOT • Cytomegalovirus – SOT and HCT • Toxoplasma gondii - HCT Well established and evidence based prophylaxis regimens

  42. West Nile Virus • A flavivirus transmitted by mosquitos, blood transfusions, transplanted organs and breast feeding” (Sanford Guide Antimicrobial Therapy 2011) • recipients of kidney or pancreas transplants, and hematopoietic stem cell transplants • In one cluster (4 organ recipients), blood transfusion was the probable source of WNV viremia in the donor • Blood is now tested in the USA due to increased serum lipase in 11/17 cases

More Related